Mixed pH-Sensitive Polymeric Micelles for Combination Drug Delivery

被引:47
作者
Bae, Younsoo [1 ]
Alani, Adam W. G. [2 ]
Rockich, Nicole C. [2 ]
Lai, T. S. Z. Chung [2 ]
Kwon, Glen S. [2 ]
机构
[1] Univ Kentucky, Coll Pharm, Lexington, KY 40536 USA
[2] Univ Wisconsin, Div Pharmaceut Sci, Sch Pharm, Madison, WI 53705 USA
基金
美国国家卫生研究院;
关键词
combination chemotherapy; drug delivery; mixed micelles; pH-controlled release; polymeric micelles; TOPOISOMERASE-II; SIGNALING PATHWAYS; ANTICANCER DRUGS; BREAST-CANCER; CELL-DEATH; HSP90; TARGET; CHEMOTHERAPY; EXPRESSION; GELDANAMYCIN;
D O I
10.1007/s11095-010-0234-3
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To prepare mixed polymeric micelles that can carry two different drugs, doxorubicin (DOX) and 17-hydroxyethylamino-17-demethoxygeldanamycin (GDM-OH), for combination cancer chemotherapy. The pH-sensitive micelles were prepared from poly(ethylene glycol)-poly(aspartate hydrazide) block copolymers to which either DOX or GDM-OH is conjugated through acid-labile hydrazone bond (individual micelles). Mixed micelles were formed not only by simply mixing two different individual micelles in aqueous solutions (aqueous mixed micelles) but also by evaporating organic solvents from the organic/aqueous mixed solvents in which two block copolymers possessing different drugs were dissolved homogeneously (organic mixed micelles). Particle size measurements, pH-dependent drug release tests, cytotoxicity assays and western blot analysis were subsequently conducted. Individual and aqueous/organic mixed micelles showed clinically relevant particle size (< 100 nm) and pH-dependent drug release patterns. Mixed polymer micelles suppress cancer cell growth effectively in a drug concentration, mixing method and schedule-dependent way. Combination chemotherapy using polymeric micelles seems to minimize a schedule-dependent change in combination drug efficacy in comparison to drug combination using DMSO formulations.
引用
收藏
页码:2421 / 2432
页数:12
相关论文
共 41 条
[31]   Drug interactions in cancer therapy [J].
Scripture, Charity D. ;
Figg, William D. .
NATURE REVIEWS CANCER, 2006, 6 (07) :546-558
[32]  
SENT, 2004, MOL PHARM, V1, P395
[33]   Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases [J].
Smalley, KSM ;
Haass, NK ;
Brafford, PA ;
Lioni, M ;
Flaherty, KT ;
Herlyn, M .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) :1136-1144
[34]   Polymer therapeutics designed for a combination therapy of hormone-dependent cancer [J].
Vicent, MJ ;
Greco, F ;
Nicholson, RI ;
Paul, A ;
Griffiths, PC ;
Duncan, R .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2005, 44 (26) :4061-4066
[35]  
West Kevin R, 2005, Curr Drug Discov Technol, V2, P123, DOI 10.2174/1570163054866882
[36]   Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer [J].
Workman, Paul ;
Powers, Marissa V. .
NATURE CHEMICAL BIOLOGY, 2007, 3 (08) :455-457
[37]   Possible effects of early treatments of Hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs [J].
Xiao, Li ;
Rasouli, Parsa ;
Ruden, Douglas M. .
CURRENT MEDICINAL CHEMISTRY, 2007, 14 (02) :223-232
[38]   Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells [J].
Xu, Wanping ;
Neckers, Len .
CLINICAL CANCER RESEARCH, 2007, 13 (06) :1625-1629
[39]   Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51 [J].
Yao, Qing ;
Weigel, Brenda ;
Kersey, John .
CLINICAL CANCER RESEARCH, 2007, 13 (05) :1591-1600
[40]   Protein kinase C δ activates topoisomerase IIα to induce apoptotic cell death in response to DNA damage [J].
Yoshida, K ;
Yamaguchi, T ;
Shinagawa, H ;
Taira, N ;
Nakayama, KI ;
Miki, Y .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (09) :3414-3431